2001 3.6
EB109/7 12 11
1. 1
WHA54.11
d d
2. (2) d2000 2003 d 3. 2001 2003 d 2000 d (3) HIV/ (4)
(1) – c c
2002 c
– –
d d2002 2003 c d –
1
20002000 WHO/EDM/2000.1
2003
EB109/7
4. d 1999 1
1977 156 d d c c d2000 d c HIV/ q d 2000 r – d1999
5. 2001
6. d HIV d c d 7. 2000 2001 c d d2000 11 c c 20 d 8. 2
– c c c
c
c
d2001 c d d c d c
1 2
EB109/8 HWO/CDS/CSR/DRS/2001.2
2
EB109/7
9. 1
300 HIV/ / / d c 2
/ 3
/
d
10. 4
d c d 5
d
11.
d d d c c d c d2002
12. 6
d d c d
/ 95 (1) ( (5)
% 2)
c (3) (6)
c d (4) d 2000 –
13.
1 2
/ 3 4 5 6
/
/ (http://www.paho.org/English/HCP/HCA/antiretrovirals HP.htm)
/ 2001 4 8-11 Hosdjor
3
EB109/7
2001 d 8 c d
50 2000 2001 9 c c 5 c c 2000 6 d c 2001
d d q
d 2001
11
rd 14. c c c c d d
15. 25% 90%d d 16. 3 d 17. 2000 2001 2002 10 d d d 65% 60% -
– 35 1
d
1
Zerda A, Velasquez G, Tobar F, Vargas ISALUD 2001 ISBN 92 75 32353 4
JE
4
EB109/7
18. d
c
c d d
19. 2002 2003 d
–
20. d
c HIV/ d c d d c c c c c
d
c d
21. d2002 d d 22. 10 d 60 20 23. c HIV/ d 1
HIV/
1
60 d d d d
d
1
120
3
WHO/DAP/98.10
5
EB109/7
24. d 40 c c c 240 c d2000 c c c d – c c c
d 2001 c – c d c
25. d2000 q d 2
r d d c
1
c
26. d 2001 3
2000 d
–
27.
d
=
=
=
1 2 3
WHO/EDM/QSM/2000.4 2001 WHA49.18 7(XXXIX) 14(1)
6